The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Open accessPublished version of a preprint
Abstract
Immunotherapeutic PD-1–targeted therapies require CD28 to promote cancer cell killing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ligation of PD-1 with its ligands programmed death-ligand 1 or 2 (PD-L1 or PD-L2) induces tyrosine phosphorylation of the PD-1 cytoplasmic domain by phosphorylating kinase Lck and subsequent recruitment of cytosolic tyrosine phosphatase SHP-2 and PD-1-associated SHP-2 preferentially dephosphorylates CD28 and suppresses CD28 costimulatory signaling leading to restrained effector T cell function (49”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [49]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overcoming such checkpoints through the use of therapeutic antibodies targeting the CTLA-4, PD-1, or PD-L1 cell-surface receptors was shown to be instrumental in promoting anti-tumor T cell responses in mice and in cancer patients”
From LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer (2018) · cites this paper as Hui et al., 2017
Experimental — accuracy not yet measuredIn the citing paper
“SHP2 also has effects on parallel pathways (e.g., JAK/STAT signaling) and is implicated as an effector of inhibitory signaling by PD-1 and some other immune checkpoint receptors (Hui et al., 2017; Peled et al., 2018; Yokosuka et al., 2012).”
From SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling (2021) · cites this paper as Hui et al., 2017
In the citing paper
“Among these, CD28 has recently been found to be the primary target (45).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [45]
In the citing paper
“The requirement for both T cell co-stimulation and IL-12 to achieve maximal IFN-γ response likely reflected the need of CD28 to rescue exhausted CD8+ T cells, and possibly also the role of PD-1 in limiting CD28-mediated co-stimulation (Kamphorst et al., 2017; Hui et al., 2017).”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Hui et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Self-citationPD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Self-citationTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Cited by
Sorted by citations
Items 801–900 of 1,002
Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors
Davar, D., & Zarour, H. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_2 · Cited by 20
Melanoma immunotherapy: strategies to overcome pharmacological resistance
Trojaniello, C., Vitale, M. G., Scarpato, L., Esposito, A., & Ascierto, P. A. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1745634 · Cited by 22
Yoo, S. Y., Badrinath, N., Jeong, S.-N., Woo, H. Y., & Heo, J. (2020) · Vaccines · doi:10.3390/vaccines8020321 · Cited by 20
Cancer and HIV-1 Infection: Patterns of Chronic Antigen Exposure
Viganó, S., Bobisse, S., Coukos, G., Perreau, M., & Harari, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01350 · Cited by 21
James, N. E., Woodman, M. F., DiSilvestro, P., & Ribeiro, J. R. (2020) · Cancers · doi:10.3390/cancers12082150 · Cited by 19
Mathew, D., & Torres, R. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.531910 · Cited by 22
Non-canonical PD-1 signaling in cancer and its potential implications in clinic
Zha, H., Jiang, Y., Wang, X., Shang, J., Wang, N., Yu, L., Zhao, W., Li, Z., Zhang, X., Zhang, X., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001230 · Cited by 24
Han, Z., Gong, C., Li, J., Guo, H., Chen, X., Jin, Y., Gao, S., & Tai, Z. (2021) · Materials Today Bio · doi:10.1016/j.mtbio.2021.100170 · Cited by 21
The importance of type I interferon in orchestrating the cytotoxic T-cell response to cancer
Busselaar, J., Sijbranda, M., & Borst, J. G. (2024) · Immunology Letters · doi:10.1016/j.imlet.2024.106938 · Cited by 21
PD-1 blockade employed at the time CD8+ T cells are activated enhances their antitumor efficacy
Moseman, J. E., Rastogi, I., Jeon, D., & McNeel, D. G. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011145 · Cited by 21
T cell adaptation in chronic infections and tumors
Luxenburger, H., Thimme, R., & Hofmann, M. (2026) · Cellular and Molecular Immunology · doi:10.1038/s41423-026-01405-y · Cited by 20
Rogers, M. C., & Williams, J. V. (2018) · Annual Review of Virology · doi:10.1146/annurev-virology-092917-043515 · Cited by 19
Roberts, A., Bentley, L., Tang, T., Stewart, F., Pallini, C., Juvvanapudi, J., Wallace, G. R., Cooper, A. J., Scott, A., THICKETT, D. R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-83612-3 · Cited by 21
Immune checkpoint inhibitor-related endocrinopathies
Lu, D., & Gao, Y. (2022) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2022-0009 · Cited by 19
Abrams, R. E., Pierre, K. K., El-Murr, N., Seung, E., Wu, L., Luna, E., Mehta, R., Li, J., Larabi, K., Ahmed, M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-14726-5 · Cited by 19
An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy
Cowles, S. C., Sheen, A. M., Santollani, L., Lutz, E. A., Lax, B. M., Palmeri, J. R., Freeman, G. J., & Wittrup, K. D. (2022) · mAbs · doi:10.1080/19420862.2022.2088454 · Cited by 21
Brunet‐Ratnasingham, E., Morou, A., Dubé, M., Niessl, J., Baxter, A. E., Tastet, O., Brassard, N., Ortega-Delgado, G.-G., Charlebois, R., Freeman, G. J., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104254 · Cited by 20
Cassioli, C., Patrussi, L., Valitutti, S., & Baldari, C. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214255 · Cited by 20
Discovery of ICOS‐Targeted Small Molecules Using Pharmacophore‐Based Screening
Calvo‐Barreiro, L., Talagayev, V., Pach, S., Abdel‐Rahman, S. A., Wolber, G., & Gabr, M. T. (2023) · ChemMedChem · doi:10.1002/cmdc.202300305 · Cited by 19
Filippis, C., Arens, K., Nzeteu, G. A. N., Reichmann, G., Waibler, Z., Crauwels, P., & van Zandbergen, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01880 · Cited by 19
CD28 between tolerance and autoimmunity: the side effects of animal models
Porciello, N., Kunkl, M., & Tuosto, L. (2018) · F1000Research · doi:10.12688/f1000research.14046.1 · Cited by 18
EF Hand Domain Family Member D2 Is Required for T Cell Cytotoxicity
Peled, M., Dragovich, M. A., Adam, K. R., Strazza, M., Tocheva, A. S., Vega, I. E., & Mor, A. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800839 · Cited by 19
PTMselect: optimization of protein modifications discovery by mass spectrometry
Perchey, R. T., Tonini, L., Tosolini, M., Fournié, J., Lopez, F., Besson, A., & Pont, F. (2019) · Scientific Reports · doi:10.1038/s41598-019-40873-3 · Cited by 19
Liu, C., Zhang, Z., Yü, P., Qin, G., Zhang, K., Maimela, N. R., Huang, L. J., Yang, S., & Zhang, Y. (2020) · Cancer Management and Research · doi:10.2147/cmar.s238174 · Cited by 17
New cytometry tools for immune monitoring during cancer immunotherapy
Sanjabi, S., & Lear, S. P. (2021) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21984 · Cited by 20
Exosomes: Potential Biomarkers and Functions in Head and Neck Squamous Cell Carcinoma
Li, T., Li, J., Wang, H., Zhao, J., Yan, M., He, H., & Yu, S. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.881794 · Cited by 18
Heidari‐Foroozan, M., Rezalotfi, A., & Rezaei, N. (2024) · International Reviews of Immunology · doi:10.1080/08830185.2024.2401352 · Cited by 19
Feng, Y., Deyanat‐Yazdi, G., Newburn, K., Potter, S. C., Wortinger, M. A., Ramirez, M., Truhlar, S. M. E., & Yachi, P. P. (2024) · Journal of Autoimmunity · doi:10.1016/j.jaut.2024.103339 · Cited by 20
The Problem with Syngeneic Mouse Tumor Models
Lönberg, N. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-1046 · Cited by 23
Li, W., Xu, M., Cheng, M., Wei, J., Zhu, L., Deng, Y., Guo, F., Bi, F., & Liu, M. (2025) · Cancer Medicine · doi:10.1002/cam4.71065 · Cited by 17
Kim, Y., Lim, S. Y., Kim, H., Ha, S., Park, J., Won, Y., Chae, S., & Lim, K. S. (2025) · Pharmaceuticals · doi:10.3390/ph18081083 · Cited by 19
From infection to immune exhaustion: The Epstein-Barr virus and its contribution to Immunosenescence
Hu, L., Zhu, T., Long, J., Luo, Q., & Lyu, X. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189421 · Cited by 20
Haku, Y., Kitaoka, K., Ichimaru, K., Hirano, T., Wang, J., Sonomura, K., Maruo, A., Hirose, S., Wang, Y., Ito, K., et al. (2026) · Nature Immunology · doi:10.1038/s41590-025-02370-w · Cited by 19
Palermo, B., Franzese, O., Donna, C. D., Panetta, M., Quintarelli, C., Sperduti, I., Gualtieri, N., Foddai, M. L., Proietti, E., Ferraresi, V., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1465163 · Cited by 18
MERTK on mononuclear phagocytes regulates T cell antigen recognition at autoimmune and tumor sites
Lindsay, R. S., Whitesell, J. C., Dew, K. E., Rodriguez, E., Sandor, A., Tracy, D., Yannacone, S. F., Basta, B. N., Jacobelli, J., & Friedman, R. S. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20200464 · Cited by 20
Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1
Hao, Y., & Cook, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.806043 · Cited by 21
Targeting Metabolic Reprogramming of T-Cells for Enhanced Anti-Tumor Response
Dabi, Y. T., Henok, A., Degechisa, S. T., & Gizaw, S. T. (2022) · Biologics · doi:10.2147/btt.s365490 · Cited by 17
The PD-1/PD-L1 Pathway: A Perspective on Comparative Immuno-Oncology
Schöniger, S., & Jasani, B. (2022) · Animals · doi:10.3390/ani12192661 · Cited by 18
Tumor-derived extracellular vesicles in the colorectal cancer immune environment and immunotherapy
Prakash, A., Gates, T. J., Zhao, X., Wangmo, D., & Subramanian, S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108332 · Cited by 19
Current studies and future promises of PD-1 signal inhibitors in cervical cancer therapy
Awadasseid, A., Zhou, Y., Zhang, K., Tian, K., Wu, Y., & Zhang, W. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114057 · Cited by 18
Lu, Y., Wang, W., & Wang, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1171671 · Cited by 19
Protein Kinase C at the Crossroad of Mutations, Cancer, Targeted Therapy and Immune Response
Aquino, A., Bianchi, N., Terrazzan, A., & Franzese, O. (2023) · Biology · doi:10.3390/biology12081047 · Cited by 19
Jiang, G., Hong, J., Sun, L., Wei, H., Gong, W., Wang, S., & Zhu, J. (2023) · International Journal of Cancer · doi:10.1002/ijc.34711 · Cited by 18
Self-citationThe role of programmed death receptor (PD‐)1/PD‐ligand (L)1 in periodontitis and cancer
Groeger, S. E., & Meyle, J. (2024) · Periodontology 2000 · doi:10.1111/prd.12548 · Cited by 19
Risk Factors for Severe Acute Graft-versus-Host Disease in Donor Graft Composition
Stikvoort, A., Gaballa, A., Solders, M., Nederlof, I., Önfelt, B., Sundberg, B., Remberger, M., Sundin, M., Mattsson, J., & Uhlin, M. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.11.026 · Cited by 19
Okamura, H., Okazaki, I., Shimizu, K., Maruhashi, T., Sugiura, D., Mizuno, R., & Okazaki, T. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.06.007 · Cited by 20
Blair, T. C., Alice, A. F., Zebertavage, L., Crittenden, M. R., & Gough, M. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.653625 · Cited by 19
T-cell-intrinsic and -extrinsic regulation of PD-1 function
Sugiura, D., Shimizu, K., Maruhashi, T., Okazaki, I., & Okazaki, T. (2021) · International Immunology · doi:10.1093/intimm/dxab077 · Cited by 17
Beattie, J., Yarmus, L. B., Wahidi, M. M., Rivera, M. P., Gilbert, C. R., Maldonado, F., Czarnecka, K., Argento, A. C., Chen, A. J., Herth, F. J. F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201712-2539pp · Cited by 18
Ji, J., Ye, P., Sun, N., Zhu, W., Yang, M., Yu, M., Yu, J., Zhang, H., Gao, Z., Zhang, N., et al. (2024) · 癌症：英文版 · doi:10.1002/cac2.12609 · Cited by 19
Zhang, Y., Wei, R., Song, G., Yang, X., Zhang, M., Liu, W., Xiong, A., Zhang, X., Li, Q., Yang, W., et al. (2024) · mAbs · doi:10.1080/19420862.2024.2419838 · Cited by 17
Self-citationTargeting SHP1 and SHP2 to suppress tumors and enhance immunosurveillance
Zhao, Y., & Jiang, L. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2024.10.008 · Cited by 19
Jiang, C., Liu, X., Wang, M., Lv, G., & Wang, G. (2019) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504018x15456687424096 · Cited by 17
RetractedHan, R., Gong, X., Zhu, Y., Liu, X., Xia, Y., Huang, Y., Zhang, M., Zhang, Y., La, X., & Ding, J. (2021) · BioMed Research International · doi:10.1155/2021/9596358 · Cited by 17
Targeting protein kinases benefits cancer immunotherapy
Zhang, Z., Bu, L., Luo, J., & Guo, J. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188738 · Cited by 18
Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer
Khadela, A. D., Chavda, V. P., Postwala, H. I., Ephraim, R., Apostolopoulos, V., & Shah, Y. B. (2023) · Cancers · doi:10.3390/cancers15020543 · Cited by 18
Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications
Li, Q., Zhou, L., Qin, S., Huang, Z., Li, B., Li, B., Yang, M., Nice, E. C., Zhu, H., & Huang, C. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115447 · Cited by 17
Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy
Mulgaonkar, A., Udayakumar, D., Yang, Y., Harris, S. F., Öz, O. K., Geethakumari, P. R., & Sun, X. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1199146 · Cited by 18
Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma
Carloni, R., Sabbioni, S., Rizzo, A., Ricci, A. D., Palloni, A., Petrarota, C., Cusmai, A., Tavolari, S., Gadaleta‐Caldarola, G., & Brandi, G. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s390963 · Cited by 18
Functional enhancement of mesothelin-targeted TRuC-T cells by a PD1-CD28 chimeric switch receptor
McCarthy, D. P., Lofgren, M., Watt, A., Horton, H. M., Kieffer-Kwon, P., Ding, J. P., Kobold, S., Baeuerle, P. A., Hofmeister, R., Gutierrez, D. A., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03556-7 · Cited by 17
The inter-link of ageing, cancer and immunity: findings from real-world retrospective study
Fu, X., Qin, P., Li, F., Zhu, H., You, H., Zhang, Y., Xu, B., Li, T., Zhang, F., Han, L., et al. (2023) · Immunity & Ageing · doi:10.1186/s12979-023-00399-9 · Cited by 19
Atomistic ensemble of active SHP2 phosphatase
Anselmi, M., & Hub, J. S. (2023) · Communications Biology · doi:10.1038/s42003-023-05682-5 · Cited by 16
Poiret, T., Vikberg, S., Schoutrop, E., Mattsson, J., & Magalhaes, I. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05063-4 · Cited by 20
Research progress of CD80 in the development of immunotherapy drugs
Li, L., Yang, L., & Jiang, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1496992 · Cited by 19
Decoding T cell senescence in cancer: Is revisiting required?
Magkouta, S., Markaki, E., Evangelou, K., Petty, R., Verginis, P., & Gorgoulis, V. G. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.11.003 · Cited by 17
Advances in immunotherapy for pediatric acute myeloid leukemia
Bonifant, C. L., Velasquez, M. P., & Gottschalk, S. M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1384463 · Cited by 17
The host protecting the tumor from the host — targeting PD‑L1 expressed by host cells
Munn, D. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99047 · Cited by 17
Aragoneses-Fenoll, L., Ojeda, G., Montes‐Casado, M., Acosta‐Ampudia, Y., Dianzani, U., Portolés, P., & Rojo, J. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00332 · Cited by 18
Zhang, J., He, T., Yin, Z., Shang, C., Xue, L., & Guo, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.864021 · Cited by 20
Chang, Z., Zhang, Q., Hu, Q., Liu, Y., Zhang, L., & Liu, R. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113543 · Cited by 19
McGee, M. C., Zhang, T., Magazine, N., Islam, R., Carossino, M., & Huang, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.984476 · Cited by 17
CD28 Costimulation of T Helper 1 Cells Enhances Cytokine Release In Vivo
Langenhorst, D., Haack, S., Göb, S., Uri, A., Lühder, F., Vanhove, B., Hünig, T., & Beyersdorf, N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01060 · Cited by 16
Lin, H., Wan, M., Yang, X., & Meng, H. (2025) · Discover Oncology · doi:10.1007/s12672-025-01997-3 · Cited by 19
Heeren, J. J. F. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.13019 · Cited by 16
Yang, C., Blaize, G., Marrocco, R., Rouquié, N., Bories, C., Gador, M., Mélique, S., Joulia, E., Benamar, M., Dejean, A. S., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abl5343 · Cited by 18
Masle‐Farquhar, E., Jeelall, Y. S., White, J. K., Bier, J., Deenick, E. K., Brink, R. A., Horikawa, K., & Goodnow, C. C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1095257 · Cited by 16
Functional DNA as a Molecular Tool in Regulating Immunoreceptor–Ligand Interactions
Sun, L., Shen, F., Qu, Y., & Liu, Z. (2023) · JACS Au · doi:10.1021/jacsau.3c00291 · Cited by 16
Friend or Foe – Tc17 cell generation and current evidence for their importance in human disease
Hipp, A. V., Bengsch, B., & Globig, A.-M. (2023) · Discovery Immunology · doi:10.1093/discim/kyad010 · Cited by 18
Hou, Q., Jiang, W., Li, W., Huang, C., Yang, K., Chen, X., Huang, M., Shu, C., Luo, G., Sun, H., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00992 · Cited by 14
Current Progress in the Science of Novel Adjuvant Nano-Vaccine-Induced Protective Immune Responses
Saleemi, M. A., Zhang, Y., & Zhang, G. (2024) · Pathogens · doi:10.3390/pathogens13060441 · Cited by 16
Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant
Chai, D., Wang, J., Fan, C., Lim, J. M., Wang, X., Neeli, P. K., Yu, X., Young, K. H., & Li, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01566-1 · Cited by 16
Sagrero‐Fabela, N., Chávez-Mireles, R., Salazar‐Camarena, D. C., & Palafox‐Sánchez, C. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147726 · Cited by 21
Yin, S., Li, C., Shen, X., Yu, G., Cui, L., Wu, Y., He, Y., Yu, S., Chen, J., Lu, S., et al. (2024) · Advanced Science · doi:10.1002/advs.202403438 · Cited by 15
Ellestad, K. K., Thangavelu, G., Haile, Y., Lin, J., Boon, L., & Anderson, C. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00012 · Cited by 16
Kim, S.-H., Singh, R., Han, C., Cho, E., Kim, Y. I., Lee, D. G., Kim, Y. H., Kim, S. S., Shin, D. H., You, H. J., et al. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00533-3 · Cited by 15
Liu, W., Zheng, X., Wang, J., He, Q., Li, J., Zhang, Z., & Liu, H. (2020) · Laboratory Medicine · doi:10.1093/labmed/lmaa110 · Cited by 16
Liu, K., Qin, Z., Xu, X., Li, T., Ge, Y., Mao, H., & Xing, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.662731 · Cited by 17
Weingarden, A. R., Rubin, S. J. S., & Gubatan, J. M. B. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i8.772 · Cited by 16
Mor, A., & Strazza, M. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.790386 · Cited by 16
Neoadjuvant chemotherapy modulates exhaustion of T cells in breast cancer patients
Rodríguez, I. J., Bernal-Estévez, D. A., Llano-León, M., Bonilla, C., & Parra-López, C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0280851 · Cited by 16
Central memory phenotype drives success of checkpoint inhibition in combination with CAR T cells
Toews, K., Grunewald, L., Schwiebert, S., Klaus, A., Winkler, A., Ali, S., Zirngibl, F., Astrahantseff, K., Wagner, D. L., Henssen, A. G., et al. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23202 · Cited by 17
Shi, X., Zhao, X., He, Y., Zhang, L., Zheng, X., Qin, X., Li, K., Li, J., Wang, Y., Dai, L., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113961 · Cited by 15
Therapeutic potential of targeting LAG-3 in cancer
Davar, D., Anderson, A. C., & Díaz-Padilla, I. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011652 · Cited by 17
Classic versus innovative strategies for immuno-therapy in pancreatic cancer
Formelli, M. G., Palloni, A., Tavolari, S., Deiana, C., Andrini, E., Marco, M. D., Campana, D., Lamberti, G., & Brandi, G. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115671 · Cited by 16
Inhibitory immune checkpoints in cancer immunotherapy
Tang, Z.-H., & Veillette, A. (2025) · Science Immunology · doi:10.1126/sciimmunol.adv6870 · Cited by 16
The Role of Programmed Death-1 in Type 1 Diabetes
Tucker, C., Dwyer, A. J., Fife, B. T., & Martinov, T. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01384-6 · Cited by 16
Characterization of Antigen-Induced CD4+ T-Cell Senescence in Multiple Sclerosis
Ojer, P. T., Puthenparampil, M., Cruciani, C., Docampo, M. J., Martinꝉ, R., & Sospedra, M. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.790884 · Cited by 15
Desai, J., Fong, P. C. C., Moreno, V., Frentzas, S., Meniawy, T. M., Markman, B., Voskoboynik, M., Rahman, T., Budha, N. R., Wu, J. C., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-022-02128-3 · Cited by 15
Regulation of PD-L1 Expression by Nuclear Receptors
Kiriyama, Y., & Nochi, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129891 · Cited by 15
Meng, Y., Wang, Y., Zhang, S., Yang, Y., Wu, D., Cui, W., Niu, X., Chu, C., Wang, L., & Qin, M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00264 · Cited by 15
Metadata
- Authors
- Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., & Vale, R. D.
- Affiliations
- Howard Hughes Medical Institute (US)
- Genentech (US)
- University of Chicago (US)
- Corresponding author
- Mellman, Ira
- Vale, Ronald D.
- ORCID
- Venue
- Science
- Published
- 2017-03-31
- Volume
- 355
- Issue
- 6332
- Pages
- 1428-1433
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC6286077
- OpenAlex
- W2592133876
- Cited by
- 1,689
- References
- 68
- Citations by year
- 2026: 121 · 2025: 158 · 2024: 201 · 2023: 203 · 2022: 193 · 2021: 218 · 2020: 224 · 2019: 159 · 2018: 143 · 2017: 63
- FWCI
- 70.99
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Science (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
- Funders
- Chicago Biomedical Consortium
- NIH (R21AI120010, R00AI106941)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- PD-1, CD28, PD-L1, T cell costimulation, T cell receptor signaling, SHP2, receptor dephosphorylation, T cell activation, anti-PD-1 therapy, cancer immunotherapy
- MeSH terms
- Animals, Humans, Immunotherapy, Lymphocyte Activation, Mice, Inbred C57BL, Neoplasms, Phosphorylation, T-Lymphocytes, CD28 Antigens, Jurkat Cells, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
